Search

Displaying results 9581 - 9590 of 9870 in total
  1. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist.

  2. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  3. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  4. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
  5. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

  6. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. … [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]

  7. Drug

    Isoaminile

    go.drugbank.com/drugs/DB08944
    ApprovedWithdrawn

    Isoaminile, an antitussive drug with a structure similar to methadone, is also an anticholinergic with both antimuscarinic and antinicotinic properties.

  8. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding … Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation.

  9. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    Fursultiamine is a vitamin B1 derivative.

  10. Drug

    Fenspiride

    go.drugbank.com/drugs/DB08979
    Investigational

    Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.